Andrea Blakeman, APRN
Community Health · Rock Hill, SCNPI 1053954438
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Boehringer Ingelheim at 34.4% of the total.
Across 9 payments — averaging $15.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$47
- Novo Nordisk$34
- Takeda Pharmaceuticals U.S.A., Inc.$15
- Organon$14
- Dexcom, Inc.$13
- Hologic Sales And Service, LLC$13
What the payments were for
- Food & beverage$136100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 3 | $47 |
| Novo Nordisk | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Organon | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Hologic Sales And Service, LLC | 1 | $13 |
How this compares
Too few community health providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 58 | $40,826 |
| JanuviaSitagliptin Phosphate | 17 | $8,568 |
| XareltoRivaroxaban | 11 | $6,493 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,996 |
| Memantine Hcl | 35 | $2,678 |
| Quetiapine Fumarate | 106 | $2,204 |
| Atorvastatin Calcium | 103 | $1,630 |
| Tramadol Hcl | 52 | $1,567 |
| Gabapentin | 48 | $1,326 |
| Trazodone Hcl | 84 | $1,306 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 47 | $1,275 |
| Levothyroxine Sodium | 90 | $1,167 |
| Duloxetine Hcl | 39 | $1,143 |
| Lorazepam | 65 | $1,120 |
| Sertraline Hcl | 80 | $1,012 |
Paid to pharmacies, not to this prescriber.
Other community health in Rock Hill
- Marcia LuisGreenville$1K
- Kay BerlandWalterboro$233
- Patricia PorterCharleston$174
- Angela RichardsNorth Charleston$89
- Stephanie BarnhillSpartanburg$80
- Karen HickmanEdgefield$39
- Amy PainterColumbia$16
- Susan LeeCharleston Afb$9
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.